CN111249371A - Composition for dispelling effects of alcohol and protecting liver and product - Google Patents

Composition for dispelling effects of alcohol and protecting liver and product Download PDF

Info

Publication number
CN111249371A
CN111249371A CN201911202646.7A CN201911202646A CN111249371A CN 111249371 A CN111249371 A CN 111249371A CN 201911202646 A CN201911202646 A CN 201911202646A CN 111249371 A CN111249371 A CN 111249371A
Authority
CN
China
Prior art keywords
product
composition
extract
bifidobacterium lactis
hangover
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911202646.7A
Other languages
Chinese (zh)
Inventor
陈醇
何剑
华彦俊
赵子夫
冯昊天
朱佳
陈奕旻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Yili Industrial Group Co Ltd
Original Assignee
Inner Mongolia Yili Industrial Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inner Mongolia Yili Industrial Group Co Ltd filed Critical Inner Mongolia Yili Industrial Group Co Ltd
Publication of CN111249371A publication Critical patent/CN111249371A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/127—Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/18—Milk in dried and compressed or semi-solid form
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
    • A23L2/84—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter using microorganisms or biological material, e.g. enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/14—Yeasts or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/113—Acidophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/165—Paracasei
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to the field of food and medicine, in particular to a composition for dispelling effects of alcohol and protecting liver and a product thereof. In particular, the invention relates to an anti-hangover and hepatoprotective composition comprising a plant extract and probiotics, and products (such as food and pharmaceutical products) comprising the anti-hangover and hepatoprotective composition.

Description

Composition for dispelling effects of alcohol and protecting liver and product
Technical Field
The invention relates to the field of food and medicines, in particular to a composition for relieving alcoholism and protecting liver and a product containing the composition.
Background
Chinese drinking culture has been a long-term source. The pleasure can be brought by drinking and important cultural functions are carried. In addition, the moderate drinking also has the functions of promoting blood circulation, dispelling cold, relieving tension and promoting metabolism. However, long-term excessive drinking can cause alcoholic liver diseases, mainly manifested as fatty liver, alcoholic hepatitis, hepatic fibrosis and liver cirrhosis, and can cause liver cancer in severe cases. Acute alcoholism refers to a process of exciting or inhibiting neuropsychiatric symptoms caused by drinking a large amount of high-concentration alcoholic beverages at one time, and is accompanied by multi-system injuries of a digestive system, a cardiovascular system and the like, and severe patients can suffer from respiratory failure and death. WHO reports that 2016 alcohol caused about 300 million deaths, accounting for 5.3% of all deaths worldwide. At present, naloxone is a common medicine for clinically treating acute alcoholism, belongs to an opioid receptor antagonist, can relieve respiratory disturbance, improve cerebral edema of a patient and promote early awakening of the patient, but easily causes adverse effects on cardiovascular system of the patient, and discomfort of nervous system and digestive system still exists after awakening.
Therefore, there is a need to develop anti-hangover and hepatoprotective products to reduce the harm of alcohol drinking to human body.
Disclosure of Invention
The invention provides a composition for relieving alcoholism and protecting liver and a product containing the composition.
In one aspect, the application provides an anti-hangover and hepatoprotective composition comprising a plant extract comprising Ampelopsis grossedentata leaf extract, Hovenia dulcis semen extract, and Pueraria lobata extract, and a probiotic comprising Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium lactis Bi-07, Bifidobacterium lactis Bl-04, and Bifidobacterium lactis HN 019.
In certain embodiments, the weight ratio of ampelopsis grossedentata leaf extract, hovenia dulcis thunb extract, pueraria lobata extract is 4-12: 1-3: 0.5 to 1.5, for example 8:2: 1.
In certain embodiments, the ratio of viable bacteria addition amounts of lactobacillus acidophilus NCFM, lactobacillus paracasei Lpc-37, bifidobacterium lactis Bi-07, bifidobacterium lactis Bl-04, bifidobacterium lactis HN019 is 1-4: 1-4: 1-4: 1-4: 4 to 10, for example 1:1:1:1: 6.
In some implementationsIn the scheme, each part of the hangover-alleviating and liver-protecting composition comprises 550-1650 mg of plant extract and 8 multiplied by 10 of probiotics9～2.6×1010colony forming unit(CFU)。
In certain embodiments, the anti-hangover and hepatoprotective composition comprises 400-1200 mg, for example 800mg, of Ampelopsis grossedentata leaf extract per serving.
In certain embodiments, the anti-hangover and hepatoprotective composition comprises 100-300 mg, such as 200mg, of Hovenia dulcis Thunb extract per serving.
In some embodiments, the anti-hangover and hepatoprotective composition comprises 50-150 mg, such as 100mg, of the kudzu root extract per serving.
In certain embodiments, lactobacillus acidophilus NCFM 1 × 10 is included in each anti-hangover and hepatoprotective composition9～4×109CFU, e.g. 1X 109CFU。
In certain embodiments, each anti-hangover and hepatoprotective composition comprises lactobacillus paracasei Lpc-371 × 109～4×109CFU, e.g. 1X 109CFU。
In certain embodiments, each part of the hangover-alleviating and liver-protecting composition comprises bifidobacterium lactis Bi-071 x 109～4×109CFU, e.g. 1X 109CFU。
In certain embodiments, Bifidobacterium lactis Bl-041X 10 is included in each anti-hangover and hepatoprotective composition9～4×109CFU, e.g. 1X 109CFU。
In certain embodiments, bifidobacterium lactis HN 0194 x 10 is included in each hangover-alleviating and liver-protecting composition9～1×1010CFU, e.g. 6X 109CFU。
In the composition of the present invention, the ampelopsis grossedentata leaf extract, hovenia dulcis thunb extract and pueraria lobata extract are generally considered to have bacteriostatic action, and those skilled in the art will not generally mix these plant extracts with probiotics to avoid the activity of the probiotics from being affected. However, the present invention uses the plant extract in combination with probiotics, which unexpectedly has good anti-hangover and liver-protecting effects.
In addition, the components in the composition can generate synergistic action, and the combination of the components can realize synergistic effect compared with the single use.
The application also relates to a product, wherein the product or the raw material of the product comprises any one of the hangover-alleviating and liver-protecting compositions.
In certain embodiments, the product is a food product, such as a general or health food, for example, a yogurt, a lactic acid bacteria beverage, a milk tablet, a solid beverage, or a tabletted candy.
In certain embodiments, the solid beverage further comprises a carrier (e.g., a sugar alcohol).
For solid beverages, plant extracts such as ampelopsis grossedentata leaf extract, hovenia dulcis thunb extract, pueraria lobata extract and the like are preferably present in different packages from the probiotics in order to avoid the influence of a small amount of moisture that may be present in the plant extracts on the probiotics.
The product of the invention can be used for shortening the drunk time and/or sobering time of a drinker, reducing the blood ethanol content level of the drinker and/or reducing the ethanol accumulation level in the blood of the drinker, or can be used for auxiliary protection of chemical liver injury (such as alcoholic liver injury).
In certain embodiments, the product is a pharmaceutical product (e.g., a Chinese patent drug) that can be used to prevent and/or treat chemical liver injury (e.g., alcoholic liver injury).
In the product of the present invention, the pharmaceutical or health food may be prepared into any dosage form suitable for oral administration, such as tablet, granule, capsule, pill or oral liquid.
In certain embodiments, each minimum sales unit of the product comprises 1-50 times (e.g., 1-fold, 5-fold, 10-fold, 15-fold, 20-fold, 30-fold, 40-fold, or 50-fold) the minimum effective dose of the anti-hangover and liver-protecting composition. For food products, the minimum sales unit can be the minimum amount a consumer purchases at one time. For pharmaceutical products, the minimum sales unit may be a prescription bolus, a minimum amount purchased by a consumer at a time, a seven day minimum bolus, or a one course bolus.
In certain embodiments, the least effective dose is the least effective dose for an adult human weighing about 70 kg. In certain embodiments, the minimum effective dose is one serving of the anti-hangover and hepatoprotective composition.
In certain embodiments, each of the smallest packaged products comprises:
400-1200 mg, for example 800mg, of Ampelopsis grossedentata leaf extract;
100-300 mg, such as 200mg, of Hovenia dulcis Thunb extract;
50-150 mg, for example 100mg, of kudzu root extract;
lactobacillus acidophilus NCFM 1 x 109～4×109CFU, e.g. 1X 109CFU；
Lactobacillus paracasei Lpc-371X 109～4×109CFU, e.g. 1X 109CFU；
Bifidobacterium lactis Bi-071 multiplied by 109～4×109CFU, e.g. 1X 109CFU；
Bifidobacterium lactis Bl-041X 109～4×109CFU, e.g. 1X 109CFU；
Bifidobacterium lactis HN 0194X 109～1×1010CFU, e.g. 6X 109CFU。
In certain embodiments, each of the smallest packaged products comprises:
2g to 6g, for example 4g, of Ampelopsis grossedentata leaf extract;
500-1500 mg, such as 1000mg, of Hovenia dulcis Thunb extract;
250-750 mg, for example 500mg, of kudzu root extract;
lactobacillus acidophilus NCFM 5 x 109～2×1010CFU, e.g. 5X 109CFU；
Lactobacillus paracasei Lpc-375 x 109～2×1010CFU, e.g. 5X 109CFU；
Bifidobacterium lactis Bi-075X 109～2×1010CFU, e.g. 5X 109CFU；
Bifidobacterium lactis Bl-045X 109～2×1010CFU, e.g. 5X 109CFU；
Bifidobacterium lactis HN 0195X 109～5×1010CFU, e.g. 3X 1010CFU。
In certain embodiments, each of the smallest packaged products comprises:
4-12 g, such as 8g, of Ampelopsis grossedentata leaf extract;
1-3 g, such as 2g, of semen Hoveniae extract;
500-1500 mg, such as 1000mg of kudzu root extract;
lactobacillus acidophilus NCFM 1 x 1010～4×1010CFU, e.g. 1X 1010CFU；
Lactobacillus paracasei Lpc-371X 1010～4×1010CFU, e.g. 1X 1010CFU；
Bifidobacterium lactis Bi-071 multiplied by 1010～4×1010CFU, e.g. 1X 1010CFU；
Bifidobacterium lactis Bl-041X 1010～4×1010CFU, e.g. 1X 1010CFU；
Bifidobacterium lactis HN 0194X 1010～1×1011CFU, e.g. 6X 1010CFU。
In the composition of the present invention, the ampelopsis grossedentata leaf extract, the hovenia dulcis thunb extract, the pueraria extract or the probiotic may each independently be used in the form of powder, i.e., in the form of ampelopsis grossedentata leaf powder, hovenia dulcis thunb powder, pueraria lobata powder or probiotic powder, respectively.
In certain embodiments, the Ampelopsis grossedentata leaf powder, Hovenia dulcis seed powder, Pueraria lobata powder, or probiotic powder each independently has a mesh size of 80-180 mesh (e.g., 80-100 mesh, 100-120 mesh, 120-140 mesh, 140-160 mesh, or 160-180 mesh).
The application also relates to a preparation method of the hangover-alleviating and liver-protecting composition, which comprises the steps of mixing, granulating or tabletting the components contained in the composition.
The application also relates to an application of any one of the hangover-alleviating and liver-protecting compositions in preparation of products.
In certain embodiments, the product is a food product, such as a general or health food, for example, a yogurt, a solid beverage, a lactic acid bacteria beverage, a milk tablet, or a tabletted candy.
In certain embodiments, the product is a solid beverage with a sugar alcohol as a carrier.
In certain embodiments, the product may be used to reduce the time to intoxication and/or the time to sober-up for a drinker, to reduce the level of alcohol content in the drinker's blood and/or to reduce the level of alcohol accumulation in the drinker's blood, or may be used for the auxiliary protection of chemical liver injury (e.g. alcoholic liver injury).
In certain embodiments, the product is a pharmaceutical product (e.g., a Chinese patent drug) that can be used to prevent and/or treat chemical liver injury (e.g., alcoholic liver injury).
The application also relates to the following technical scheme:
scheme 1: an anti-alcohol and liver-protecting composition comprises plant extracts and probiotics, wherein the plant extracts comprise ampelopsis grossedentata leaf powder, hovenia dulcis thunb powder and pueraria lobata powder, and the probiotics comprise lactobacillus acidophilus NCFM, lactobacillus paracasei Lpc-37, bifidobacterium lactis Bi-07, bifidobacterium lactis Bl-04 and bifidobacterium lactis HN 019;
preferably, the adding amount ratio of the ampelopsis grossedentata leaf powder, the hovenia dulcis thunb powder and the pueraria lobata powder is 4-12: 1-3: 0.5-1.5;
preferably, the ratio of the viable bacteria addition amount of lactobacillus acidophilus NCFM, lactobacillus paracasei Lpc-37, bifidobacterium lactis Bi-07, bifidobacterium lactis Bl-04 and bifidobacterium lactis HN019 is 1-4: 1-4: 1-4: 1-4: 4-10.
Scheme 2: a product, e.g. a food, e.g. a general food or a health food, such as a yoghurt, a lactic acid bacteria beverage, a milk tablet, a solid beverage or a tabletted candy, comprising the anti-hangover and hepatoprotective composition of scheme 1.
Scheme 3: the preparation method of the hangover-alleviating and liver-protecting composition according to the scheme 1 comprises the steps of mixing, granulating or tabletting the components contained in the composition.
Scheme 4: use of the anti-hangover and hepatoprotective composition of scheme 1 for the preparation of a product, preferably a food, such as a general food or a health food, such as yogurt, lactic acid bacteria beverage, milk tablet, solid beverage or tabletted candy.
Definition of terms
In the present application, unless otherwise specified, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art, however, in order to better understand the present invention, definitions of some terms are provided below. Where the definitions and explanations of terms provided herein do not conform to the meanings commonly understood by those skilled in the art, the definitions and explanations of terms provided herein shall control.
As used herein, the term "Ampelopsis grossedentata leaf extract" refers to an extract derived from the stem and leaves of Ampelopsis grossedentata belonging to the genus Ampelopsis of the family Vitaceae, by an aqueous extraction method, and the main active ingredient may comprise flavonoids.
As used herein, the term "hovenia dulcis thunb extract" refers to an extract derived from dried mature seeds of hovenia dulcis thunb, a plant belonging to the genus hovenia of the family rhamnaceae, by an extraction method which may be water, and the main active ingredient may comprise alkaloid, flavone and/or saponin, etc.
As used herein, the term "pueraria extract" refers to an extract derived from the dried root of pueraria lobata, pueraria lobata or pueraria lobata of leguminosae, which may be extracted with water, and the main active ingredient may include isoflavones, triterpenes and/or coumarins, etc.
As used herein, the term "anti-hangover" refers to the effect of reducing the time a drinker is intoxicated and/or the time of sobering up, reducing the alcohol content in the drinker's blood and/or reducing the accumulation of alcohol in the drinker's blood.
As used herein, the term "liver protection" refers to the action of protecting the liver, reducing liver damage (e.g., reducing alcoholic liver damage).
Advantageous effects
The composition or product of the invention can improve the discomfort after drinking, shorten the drunk time and/or sober-up time of drinkers, reduce the blood ethanol content of drinkers and/or reduce the ethanol accumulation in the blood of drinkers. The composition or product of the present invention can be taken before drinking to prevent drunkenness. In addition, the composition or the product of the invention has auxiliary protection effect on alcoholic liver injury.
Embodiments of the present invention will be described in detail below with reference to the drawings and examples, but those skilled in the art will understand that the following drawings and examples are only for illustrating the present invention and are not to be construed as limiting the scope of the present invention. Various objects and advantageous aspects of the present invention will become apparent to those skilled in the art from the accompanying drawings and the following detailed description of the preferred embodiments.
Drawings
FIG. 1 shows the blood ethanol content curve of rat in Experimental example 2.
FIG. 2 shows the effect of the composition of the present invention on MDA (FIG. 2A), GSH (FIG. 2B), TG (FIG. 2C) in liver tissue of mice with alcoholic liver injury in Experimental example 3; the ordinate of FIG. 2A is the MDA content (unit: nmol/mgprot), the ordinate of FIG. 2B is the GSH content (unit: mg/gpprot), and the ordinate of FIG. 2C is the TG content (unit: mmol/gpprot).
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but those skilled in the art will appreciate that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
Preparation of the anti-hangover and hepatoprotective composition
Raw materials:
the ampelopsis grossedentata leaf extract (Jianshi Star Biotechnology research and development (Shanghai) Co., Ltd., batch No. 171115, actually measured dihydromyricetin content 53.66%);
kudzu root extract (Jianshixing Biotechnology research & development (Shanghai) Co., Ltd., batch No. 180622, actual measurement of puerarin content 8.3%);
hovenia dulcis thunb extract (Jianshi xing biotechnology research and development (Shanghai) Co., Ltd., batch No. 180515, actually measured content of dihydromyricetin is 6.5%);
mixed probiotic powder (danisc (china) investment limited) containing per gram: lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, Bifidobacterium lactis Bi-07, Bifidobacterium lactis Bl-04 each 5 × 108CFU and Bifidobacterium lactis HN 0193X 109CFU。
Preparation: the haplotype formulation was determined based on the daily dose of 70kg human, as shown in Table 1. The raw materials were mixed according to the formulation of table 1.
TABLE 1
Composition (I) Adding the additive in each part
Ampelopsis grossedentata leaf extract 800mg
Semen Hoveniae extract 200mg
Kudzu root extract 100mg
Lactobacillus acidophilus NCFM 1×109CFU
Lactobacillus paracasei Lpc-37 1×109CFU
Bifidobacterium lactis Bi-07 1×109CFU
Bifidobacterium lactis Bl-04 1×109CFU
Bifidobacterium lactis HN019 6×109CFU
Experimental example the composition of the present invention is used for the research of the hangover alleviating effect of an alcoholic intoxication model and the evaluation of the protective effect of alcoholic liver injury
1. Experimental Material
Materials and reagents: the anti-hangover and hepatoprotective composition of example 1; 56% (V/V) Hongxing Erguotou white spirit (Beijing Hongxing GmbH); reduced Glutathione (GSH) assay kit, Malondialdehyde (MDA) assay kit, and Triglyceride (TG) assay kit (sigma aldrich trade ltd).
Instruments and equipment: spectrophotometer, ultra-high speed refrigerated centrifuge, Agilent 7890A gas chromatograph, electronic balance.
Experimental animals:
SD male rats (8 weeks old, 220-240 g), male Kunming mice (8 weeks old, 18-20 g), provided by Beijing Wittingli experiment technology Limited; license number: SCXK (Jing) 2014-. Animals are raised in animal laboratories of the institute of occupational health and poisoning control of the Chinese disease prevention and control center, room temperature (25 +/-2 ℃), relative humidity (55 +/-2)%, 12h/12h illumination, and free food intake and drinking.
2. Sample preparation
Preparing a mouse experimental sample:
in the mouse experiment, 1 time, 5 times and 10 times of the human body dose are respectively used as the low dose, the medium dose and the high dose of the mouse experiment, the required amount of a 20g mouse sample is calculated according to the conversion coefficient of 70kg human body dose and 20g mouse dose of 0.0026, the stomach filling dose of the mouse is 2mL/100g bw (bw: body weight) during preparation, and the specific dose is shown in table 2.
TABLE 2 mouse body dose table (unit: mg)
Figure BDA0002296242100000091
According to the daily mouse sample requirement, 10mL of each sample is prepared for intragastric administration, and the table shows the amount of the sample required for preparing 10mL of intragastric administration solution for each dosage group.
Preparation of experimental samples of rats:
in rat experiments, 1 time, 5 times and 10 times of human body dose are taken as rat dose, a conversion coefficient of 70kg human body dose and 200g rat dose is referred to be 0.018, 2.0mL/100g bw is taken as rat gavage dose during preparation, and specific dose is shown in table 3.
TABLE 3 rat body dosage table (unit: mg)
Figure BDA0002296242100000092
According to the gavage dosage and the volume of the rats, 100mL of each dose of the gavage liquid is prepared by each gavage.
3. Data processing
The behavioral index data are expressed as mean ± standard deviation, median and quartile, and the other data are expressed as mean ± standard deviation. SAS 9.4 software is adopted for data analysis, and single-factor method analysis or rank-sum inspection is adopted for significance comparison among groups. The difference is statistically significant with p < 0.05.
Experimental example 1 behavioral Observation experiment
The experimental method comprises the following steps:
80 mice, after 3 days of acclimation, were randomly divided into 4 groups of 20 mice each, based on body weight. And before the experiment, the patient is fasted and water is not forbidden for 12 hours. The experimental group was administered with different doses of anti-hangover composition (1, 5 and 10 times of the human dose as low, medium and high dose of experiment), respectively, at a gavage dose of 2mL/100g bw, and the control group was administered with distilled water, and the gavage time was recorded. After 30min of administration, each group was drenched with 56% (V/V) Hongxing Erguotou 0.19mL/10g body weight, and the behavioral indexes of the mice were observed.
After the mice were drenched with white spirit, they were immediately placed on a vertical metal net, and the climbing time of the mice on the metal net was recorded.
And continuously observing the activity condition of the mouse, and recording the drunkenness time and the sobering time of the mouse. The drunk time is the righting reflex recovery time-righting reflex disappearance time. Sobering-up time is the righting reflex recovery time-drinking time. The drunk time is the comprehensive embodiment of drunk latency and sleeping time.
The experimental results are as follows:
the results of the experiment are shown in table 4.
Table 4 effect of the composition of the invention on behavioural indicators of drunk mice
Figure BDA0002296242100000101
Note: the data in the table are: mean. + -. standard deviation (median, P25-P75 quantile) for the distribution of climax, intoxication and sober-up times.
As shown in table 4, each group of test mice exhibited greater intra-group individual variability in climbing time, intoxication time and sobering time. Compared with the average climbing time (5.85 +/-4.42 min) of the mice in the model control group, the climbing time distribution of the mice in each dose experiment group is basically consistent. Compared with the average drunkenness time (482.79 +/-227.39 min) and the median and quartile (577min, P25-P75: 511-634 min) of the mice in the model groups, the average drunkenness time of the mice in each dose experiment group is shortened to a certain degree, and the average drunkenness time of the mice in the low dose experiment group and the average drunkenness time of the mice in the medium dose experiment group are respectively shortened by 8.5 percent and 11.51 percent. Compared with the average value of the sobering time of the mice in the model control group (626.05 +/-68.04 min), the median and the quartile (630min, P25-P75: 571-683 min), the average value of the sobering time of the mice in the low-dose and medium-dose experimental groups is shortened to a certain extent and is respectively 11.30 percent and 15.07 percent.
Experimental example 2 ethanol content measurement
The experimental method comprises the following steps:
after 3 days of acclimation, 40 rats were randomly divided into 4 groups of 10 rats each according to body weight. Fasting for 12h before the experiment, and water is forbidden. The experimental group is respectively given different doses of the anti-alcoholism composition with the intragastric administration dose of 2mL/100g bw (respectively according to the conversion method of the animal pharmacology experiment medication, the conversion coefficient of 70kg human body dose and 200g rat dose is 0.018, and 1 time, 5 times and 10 times of the human body dose are taken as the low dose, the medium dose and the high dose of the experiment), the control group is given distilled water, and the intragastric administration time is recorded. After 30min, each group was gavaged with 56% white wine at 1.33mL/100g bw and the gavage time was recorded. Blood is taken from inner canthus at four time points of 0.5h, 1.0h, 2.0h and 3.0h after wine filling respectively, and the content of blood ethanol is detected by adopting a gas chromatograph.
The experimental results are as follows:
FIG. 1 shows the curve of ethanol content in rat blood, wherein ▲ shows that the difference is significant compared with the model control group, p is less than 0.05, as shown in the figure, after 0.5h of alcohol filling, the ethanol content in the model control group is 3.08 +/-0.85 mg/mL, the ethanol level continuously rises but tends to be stable within 1h to 3h, compared with the model control group, the ethanol content in each dose experiment group is lower, the ethanol level in the blood shows obvious difference, at 0.5h, the ethanol content in the medium dose and the high dose experiment group is obviously lower than that in the model control group, the ethanol content in the 1h low dose and the ethanol content in the medium dose experiment group is obviously lower than that in the model control group, and the difference in each group has statistical significance (p is less than 0.05).
The results of the area under the blood ethanol curve of the rat (showing the accumulation degree of ethanol in the blood of the rat) are shown in table 5, the area under the blood ethanol curve of the rat in the experimental group with different dosages at each time point is obviously lower than that of the model control group, and the difference between the middle dose group and the high dose group with 0.5h and 1.0h and the model control group has statistical significance (p is less than 0.05). The above results show that the composition of the present invention can rapidly reduce the blood ethanol content level of rats and reduce the accumulation level of ethanol in blood.
TABLE 5 area under the curve of the ethanol content in rat blood (unit: mg/mL. h)
Figure BDA0002296242100000121
Note: indicates that the difference is significant compared with the model control group, and p is less than 0.05.
Experimental example 3 evaluation of protective action against alcoholic liver injury
Refer to "health food function evaluation program and technical Specification", evaluation method of auxiliary protection function for chemical liver injury, alcoholic liver injury model ", issued by Ministry of health. After adaptive feeding of 70 mice for 3 days, they were randomly divided into 5 groups of 14 mice each based on body weight. Experimental settings were blank control, model control, low dose, medium dose and high dose (methods above). The experimental group is given with different dosages of the anti-inebriation composition to be tested at the dosage of 0.4mL/20g bw every day, and the blank control group and the model control group are given with distilled water, and the intervention period is 45 days. And (3) feeding 12mL/kg bw of 50% ethanol to the model control group and each dose experiment group by intragastric administration at one time at the end of the intervention period to establish an acute alcoholic liver injury model, feeding distilled water to the blank control group, and killing the animals after fasting for 16 h. A part of liver of a mouse is taken and placed in physiological saline to prepare 10% liver homogenate for MDA, GSH and TG detection.
The experimental results are as follows:
FIG. 2 shows the effect of the composition of the present invention on MDA, GSH, TG in liver tissue of mice with alcoholic liver injury, wherein a indicates the significance of the difference compared with the blank control (p < 0.05) and a # indicates the significance of the difference compared with the model control (p < 0.05). The ordinate of FIG. 2A is the MDA content (unit: nmol/mgprot), the ordinate of FIG. 2B is the GSH content (unit: mg/gpprot), and the ordinate of FIG. 2C is the TG content (unit: mmol/gpprot).
As shown in FIGS. 2A, 2B and 2C, compared with the MDA (5.22 + -0.71 nmol/mgprot), GSH (5.52 + -0.37 mg/gpprot) and TG (0.80 + -0.14 mmol/gpprot) of the mice in the blank control group, the MDA and TG contents of liver tissues of the mice in the model control group are significantly higher than those in the blank control group, the GSH content is significantly lower than that in the blank control group, and the difference has statistical significance (p is less than 0.05), which indicates that the alcohol-induced hepatocytes generate certain damage and the modeling is successful.
Compared with a model control group, the liver tissue homogenate MDA content of mice in each dose group is reduced, and the MDA content of low, medium and high dose groups is reduced by 7.61%, 27.37% and 26.50%, wherein, the difference between the low dose group and the high dose group has statistical significance (p is less than 0.05). Compared with the model control group, the mouse GSH content of each dose group is obviously increased, wherein the GSH content is 38.98%, 21.11% and 31.32%, and the difference is statistically significant (p is less than 0.05). The TG content of mice in each dose group is obviously lower than that of a model control group, namely 37.50%, 42.76% and 41.45%, and the difference has statistical significance (p is less than 0.05). In conclusion, the composition provided by the invention can be used for intervention for a long time, so that the MDA and TG contents of liver tissues of a mouse model with alcoholic liver injury can be effectively reduced, and the GSH content can be increased.
The experiments prove that the composition can shorten the drunk time and the sobering-up time of a subject, reduce the blood ethanol content level of the subject, reduce the ethanol accumulation level in blood and have auxiliary protection effect on alcoholic liver injury. In conclusion, the composition has the effects of relieving alcoholism and protecting liver.
The above-mentioned embodiments are intended to illustrate the objects, technical solutions and advantages of the present invention in further detail, and it should be understood that the above-mentioned embodiments are only exemplary embodiments of the present invention, and are not intended to limit the scope of the present invention, and any modifications, equivalent substitutions, improvements and the like made within the spirit and principle of the present invention should be included in the scope of the present invention.

Claims (9)

1. An anti-alcohol and liver-protecting composition comprises plant extracts and probiotics, wherein the plant extracts comprise a Ampelopsis grossedentata leaf extract, a hovenia dulcis thunb extract and a kudzu root extract, and the probiotics comprise lactobacillus acidophilus NCFM, lactobacillus paracasei Lpc-37, bifidobacterium lactis Bi-07, bifidobacterium lactis Bl-04 and bifidobacterium lactis HN 019.
2. The anti-hangover and hepatoprotective composition of claim 1, having one or more of the following characteristics:
(1) the weight ratio of the ampelopsis grossedentata leaf extract to the hovenia dulcis thunb extract to the pueraria extract is 4-12: 1-3: 0.5 to 1.5;
(2) the ratio of the viable bacteria addition amount of lactobacillus acidophilus NCFM, lactobacillus paracasei Lpc-37, bifidobacterium lactis Bi-07, bifidobacterium lactis Bl-04 and bifidobacterium lactis HN019 is 1-4: 1-4: 1-4: 1-4: 4-10;
(3) composition bag for relieving alcoholism and protecting liverContains 550-1650 mg of plant extract and 8 multiplied by 10 of probiotics9～2.6×1010CFU。
3. A product, or starting material for said product, comprising the anti-hangover and hepatoprotective composition of claim 1 or 2.
4. The product according to claim 3, which is a food product, such as a general food or a health food, such as a yoghurt, a lactic acid bacteria drink, a milk tablet, a solid drink or a tabletted candy.
5. The product of claim 3, which is a pharmaceutical product (e.g., a Chinese patent drug);
preferably, the medicament is for the prevention and/or treatment of chemical liver injury (e.g. alcoholic liver injury).
6. A process for preparing a hangover-alleviating and hepatoprotective composition according to claim 1 or 2, comprising mixing, granulating or tableting the ingredients comprising the composition.
7. Use of the anti-hangover and hepatoprotective composition of claim 1 or 2 for the preparation of a product.
8. Use according to claim 7, said product being a food product, such as a general food product or a health food product, such as a yoghurt, a solid drink, a lactic acid bacteria drink, a milk tablet or a tabletted candy.
9. The use of claim 7, said product being a pharmaceutical (e.g. a Chinese patent medicine);
preferably, the medicament is for the prevention and/or treatment of chemical liver injury (e.g. alcoholic liver injury).
CN201911202646.7A 2018-11-30 2019-11-29 Composition for dispelling effects of alcohol and protecting liver and product Pending CN111249371A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811455195 2018-11-30
CN2018114551953 2018-11-30

Publications (1)

Publication Number Publication Date
CN111249371A true CN111249371A (en) 2020-06-09

Family

ID=70923786

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911205090.7A Pending CN111249347A (en) 2018-11-30 2019-11-29 Composition for dispelling effects of alcohol and protecting liver and product
CN201911202646.7A Pending CN111249371A (en) 2018-11-30 2019-11-29 Composition for dispelling effects of alcohol and protecting liver and product

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201911205090.7A Pending CN111249347A (en) 2018-11-30 2019-11-29 Composition for dispelling effects of alcohol and protecting liver and product

Country Status (1)

Country Link
CN (2) CN111249347A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111249347A (en) * 2018-11-30 2020-06-09 内蒙古伊利实业集团股份有限公司 Composition for dispelling effects of alcohol and protecting liver and product
CN112007092A (en) * 2020-09-29 2020-12-01 北京佳福瑞生物科技有限公司 Anti-alcohol composition and preparation method thereof
CN115956674A (en) * 2022-12-06 2023-04-14 安徽全康药业有限公司 Health food for protecting liver and preparation method thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112569323A (en) * 2020-12-31 2021-03-30 上海交大昂立股份有限公司 Composition for dispelling effects of alcohol and protecting liver and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106266105A (en) * 2016-09-05 2017-01-04 三株福尔制药有限公司 A kind of probiotics fermention Chinese medicine composition of Antialcoholic liver-protecting and its preparation method and application
CN107007813A (en) * 2017-05-27 2017-08-04 云南德彩堂生物医药科技有限公司 A kind of efficient relieving alcoholism and protecting liver composition, its preparation method and application
CN108208853A (en) * 2018-01-04 2018-06-29 山东凤凰生物有限公司 A kind of relieving alcoholism and protecting liver probiotics oligopeptide compound formulation and preparation method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101518351B (en) * 2009-03-27 2012-02-29 武汉市久共合生物科技有限公司 Weak alkali plant alcohol intoxication-alleviating beverage and method for preparing same
CN103393097A (en) * 2013-08-02 2013-11-20 永安康健药业（武汉）有限公司 Health food with effects of sobering and protecting liver
CN105639630A (en) * 2016-01-15 2016-06-08 尚虹 Composite anti-fatigue anti-alcoholism composition with radix puerariae, raisin tree seeds and taurine being main raw materials
CN107568736A (en) * 2017-07-04 2018-01-12 劲膳美食品股份有限公司 Dealcoholic sobering-up medical science formula food
CN111249347A (en) * 2018-11-30 2020-06-09 内蒙古伊利实业集团股份有限公司 Composition for dispelling effects of alcohol and protecting liver and product

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106266105A (en) * 2016-09-05 2017-01-04 三株福尔制药有限公司 A kind of probiotics fermention Chinese medicine composition of Antialcoholic liver-protecting and its preparation method and application
CN107007813A (en) * 2017-05-27 2017-08-04 云南德彩堂生物医药科技有限公司 A kind of efficient relieving alcoholism and protecting liver composition, its preparation method and application
CN108208853A (en) * 2018-01-04 2018-06-29 山东凤凰生物有限公司 A kind of relieving alcoholism and protecting liver probiotics oligopeptide compound formulation and preparation method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
潭菊须倩: "ADB显齿蛇葡萄叶葛根糖果压片真的能解酒吗？价格大概的范围有", 《百度》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111249347A (en) * 2018-11-30 2020-06-09 内蒙古伊利实业集团股份有限公司 Composition for dispelling effects of alcohol and protecting liver and product
CN112007092A (en) * 2020-09-29 2020-12-01 北京佳福瑞生物科技有限公司 Anti-alcohol composition and preparation method thereof
CN115956674A (en) * 2022-12-06 2023-04-14 安徽全康药业有限公司 Health food for protecting liver and preparation method thereof

Also Published As

Publication number Publication date
CN111249347A (en) 2020-06-09

Similar Documents

Publication Publication Date Title
CN111249371A (en) Composition for dispelling effects of alcohol and protecting liver and product
TWI324068B (en) Antiallergic composition
EP2083809B1 (en) Dietary or pharmaceutical compositions containing tricyclic diterpenes for the treatment of depression.
JP2009502958A (en) How to treat or manage stress
WO2006042479A9 (en) Pharmaceutical composition and non dependence coffee comprising edible carboxylic acid and/or its acid salt and coffeine
EP2792364A1 (en) Composition for preventing or treating hangover
RU2475256C2 (en) Therapeutic herbal extract having action on obesity
EP1930019A1 (en) Rosemary extracts, dietary and pharmaceutical compositions containing them and their uses
JP6204913B2 (en) Epicatechin to reduce allergic symptoms
JP5537151B2 (en) Tranquilizers and functional foods
JP2018516987A (en) Pharmaceutical composition or health functional food for prevention and treatment of metabolic disease containing water extract of Aso as active ingredient
CN112294821B (en) Application of 5-methyltetrahydrofolic acid and composition thereof
KR101447760B1 (en) Dietary and pharmaceutical compositions comprising a sage extract containing a mixture of tricyclic diterpenes and their derivatives and their uses
CN108420890B (en) Composition with blood fat reducing effect and preparation method thereof
CN103920140B (en) A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation
KR101680013B1 (en) Pharmaceutical composition for preventing or treating allergic diseases comprising extrat of Pterocarpus indicus Willd as an active ingredient
CN114028444A (en) Probiotic composition and application thereof in relieving depression and reducing fat accumulation
CN111195298A (en) Composition for regulating intestinal flora and preventing and treating food allergy and preparation method thereof
JP7301810B2 (en) Peptides that improve cognitive function
KR101568044B1 (en) Composition reducing anxiety and stress
EP3960189A1 (en) Antiviral composition having antiviral activity against coronavirus and variant viruses thereof
WO2020040216A1 (en) Core body temperature reducing agent, food product, and sleep aid
JP2006042664A (en) Health food containing extract from lotus young sprout
KR20230094888A (en) Composition for protecting against alcoholic liver damage or alcohol brain damage, comprising Apios Americana tuber extract
KR20190015423A (en) Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulae (Pf.). for treating or preventing metabolic disorder

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200609